Dementia with Lewy Bodies

 

 Permissions and Reprints

Abstract

Dementia with Lewy bodies (DLB) is the second most common diagnosis of dementia after Alzheimer disease (AD). The essential pathologic feature is the Lewy body, a neuronal inclusion containing α-synuclein, found in brainstem nuclei and the neocortex. Clinical features include early fluctuations in attention, hallucinations, and parkinsonism, with progression to a combined cortical and subcortical dementia. To distinguish it from Parkinson disease dementia, a time course of one year from cognitive changes to motor feature onset has been established. There is more severe impairment of verbal fluency, executive function, and visuospatial abilities in DLB patients. Both rapid eye movement sleep behavior disorder and neuroleptic sensitivity are notable in this patient group. Treatment is aimed at symptom management. Cholinesterase inhibitors can be beneficial for behavioral and cognitive issues, whereas dopaminergic agents may help motor symptoms. Survival is equivalent to AD when measured from symptom onset, though diagnosis in DLB may be delayed.

• References

• 1 Heidebrink JL. Is dementia with Lewy bodies the second most common cause of dementia?. J Geriatr Psychiatry Neurol 2002; 15 (4) 182-187
  CrossrefPubMedGoogle Scholar
• 2 Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990; 237 (3) 197-204
  CrossrefPubMedGoogle Scholar
• 3 Chan SS, Chiu HF, Lam LC, Leung VP. Prevalence of dementia with Lewy bodies in an inpatient psychogeriatric population in Hong Kong Chinese. Int J Geriatr Psychiatry 2002; 17 (9) 847-850
  CrossrefPubMedGoogle Scholar
• 4 Shergill S, Mullan E, D'Ath P, Katona C. What is the clinical prevalence of Lewy body dementia?. Int J Geriatr Psychiatry 1994; 9 11: 907-912
  PubMedGoogle Scholar
• 5 Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 2013; 70 (11) 1396-1402
  CrossrefPubMedGoogle Scholar
• 6 McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994; 165 (3) 324-332
  CrossrefPubMedGoogle Scholar
• 7 Galasko D, Katzman R, Salmon DP, Hansen L. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996; 31 (2) 166-175
  CrossrefPubMedGoogle Scholar
• 8 Gardner RC, Valcour V, Yaffe K. Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther 2013; 5 (4) 27
  CrossrefPubMedGoogle Scholar
• 9 Benjamin R, Leake A, Edwardson JA , et al. Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet 1994; 343 (8912) 1565
  PubMedGoogle Scholar
• 10 Mata IF, Samii A, Schneer SH , et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008; 65 (3) 379-382
  PubMedGoogle Scholar
• 11 Nalls MA, Duran R, Lopez G , et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013; 70 (6) 727-735
  CrossrefPubMedGoogle Scholar
• 12 Lewy F, In: Lewandowsky MH, Bumke O. , eds. Handbuch der Neurologie. Vol. 3. Berlin, Germany: Springer; 1912: 920-933
  Google Scholar
• 13 Kosaka K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 1978; 42 (2) 127-134
  CrossrefPubMedGoogle Scholar
• 14 Kosaka K. Diffuse Lewy body disease. Neuropathology 2000; 20 (Suppl): S73-S78
  CrossrefPubMedGoogle Scholar
• 15 McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9 (3, Suppl) 417-423
  PubMedGoogle Scholar
• 16 Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47 (5) 1113-1124
  CrossrefPubMedGoogle Scholar
• 17 Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 2014; 88 (4) 508-516
  CrossrefPubMedGoogle Scholar
• 18 Zarranz JJ, Alegre J, Gómez-Esteban JC , et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55 (2) 164-173
  CrossrefPubMedGoogle Scholar
• 19 Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 2003; 40 (3) 453-456
  CrossrefPubMedGoogle Scholar
• 20 Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120 (2) 131-143
  CrossrefPubMedGoogle Scholar
• 21 Masliah E, Mallory M, DeTeresa R, Alford M, Hansen L. Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies. Brain Res 1993; 617 (2) 258-266
  CrossrefPubMedGoogle Scholar
• 22 McKeith IG, Dickson DW, Lowe J , et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-1872
  CrossrefPubMedGoogle Scholar
• 23 Ballard C, Aarsland D, Francis P, Corbett A. Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging 2013; 30 (8) 603-611
  CrossrefPubMedGoogle Scholar
• 24 Ballard C, Piggott M, Johnson M , et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48 (6) 868-876
  CrossrefPubMedGoogle Scholar
• 25 Sharp SI, Ballard CG, Ziabreva I , et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2008; 26 (4) 330-338
  CrossrefPubMedGoogle Scholar
• 26 Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol 2007; 27 (1) 42-47
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Hickey C, Chisholm T, Passmore MJ, O'Brien JD, Johnston J. Differentiating the dementias. Revisiting synucleinopathies and tauopathies. Curr Alzheimer Res 2008; 5 (1) 52-60
  CrossrefPubMedGoogle Scholar
• 28 Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004; 31 (1) 7-21
  CrossrefPubMedGoogle Scholar
• 29 Aarsland D, Perry R, Larsen JP , et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005; 66 (5) 633-637
  PubMedGoogle Scholar
• 30 Grace J, Daniel S, Stevens T , et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 2001; 13 (2) 199-205
  CrossrefPubMedGoogle Scholar
• 31 Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS ONE 2009; 4 (5) e5521
  CrossrefPubMedGoogle Scholar
• 32 Ropper AH, Samuels MA. Adams and Victor's Principles of Neurology. 9th ed. New York, NY: McGraw-Hills; 2009
  Google Scholar
• 33 Shimomura T, Mori E, Yamashita H , et al. Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998; 55 (12) 1547-1552
  CrossrefPubMedGoogle Scholar
• 34 Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003; 16 (4) 229-237
  CrossrefPubMedGoogle Scholar
• 35 Salmon DP, Galasko D, Hansen LA , et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996; 31 (2) 148-165
  CrossrefPubMedGoogle Scholar
• 36 Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997; 62 (3) 243-252
  CrossrefPubMedGoogle Scholar
• 37 Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005; 20 (Suppl. 12) S11-S20
  PubMedGoogle Scholar
• 38 Hansen L, Salmon D, Galasko D , et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990; 40 (1) 1-8
  PubMedGoogle Scholar
• 39 Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70 (2) 157-164
  CrossrefPubMedGoogle Scholar
• 40 Gill DP, Hubbard RA, Koepsell TD , et al. Differences in rate of functional decline across three dementia types. Alzheimers Dement 2013; 9 (5, Suppl) S63-S71
  CrossrefPubMedGoogle Scholar
• 41 Walker Z, McKeith I, Rodda J , et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open 2012; 2: e000380
  PubMedGoogle Scholar
• 42 Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. Eur J Neurol 2009; 16 (2) 212-217
  CrossrefPubMedGoogle Scholar
• 43 Ballard C, O'Brien J, Morris CM , et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16 (5) 499-503
  CrossrefPubMedGoogle Scholar
• 44 Walker Z, Allen RL, Shergill S, Mullan E, Katona CL. Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15 (3) 267-273
  CrossrefPubMedGoogle Scholar
• 45 Nelson PT, Jicha GA, Kryscio RJ , et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010; 257 (3) 359-366
  CrossrefPubMedGoogle Scholar
• 46 Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999; 52 (6) 1153-1158
  CrossrefPubMedGoogle Scholar
• 47 Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54 (6) 1304-1309
  CrossrefPubMedGoogle Scholar
• 48 Chow N, Aarsland D, Honarpisheh H , et al. Comparing hippocampal atrophy in Alzheimer's dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2012; 34 (1) 44-50
  CrossrefPubMedGoogle Scholar
• 49 Watson R, Blamire AM, Colloby SJ , et al. Characterizing dementia with Lewy bodies by means of diffusion tensor imaging. Neurology 2012; 79 (9) 906-914
  CrossrefPubMedGoogle Scholar
• 50 Bozzali M, Falini A, Cercignani M , et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005; 128 (Pt 7) 1595-1604
  CrossrefPubMedGoogle Scholar
• 51 Firbank MJ, Blamire AM, Teodorczuk A, Teper E, Mitra D, O'Brien JT. Diffusion tensor imaging in Alzheimer's disease and dementia with Lewy bodies. Psychiatry Res 2011; 194 (2) 176-183
  CrossrefPubMedGoogle Scholar
• 52 Mosconi L, Tsui WH, Herholz K , et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49 (3) 390-398
  CrossrefPubMedGoogle Scholar
• 53 Perneczky R, Haussermann P, Diehl-Schmid J , et al. Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study. Dement Geriatr Cogn Disord 2007; 23 (6) 416-422
  CrossrefPubMedGoogle Scholar
• 54 Imamura T, Ishii K, Sasaki M , et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 1997; 235 (1-2) 49-52
  CrossrefPubMedGoogle Scholar
• 55 Zhao P, Zhang B, Gao S. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012; 18 (Suppl. 01) S60-S62
  PubMedGoogle Scholar
• 56 Lobotesis K, Fenwick JD, Phipps A , et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56 (5) 643-649
  CrossrefPubMedGoogle Scholar
• 57 Bonanni L, Thomas A, Onofrj M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-1872
  CrossrefPubMedGoogle Scholar
• 58 Yoshita M, Taki J, Yokoyama K , et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006; 66 (12) 1850-1854
  CrossrefPubMedGoogle Scholar
• 59 Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. J Alzheimers Dis 2014; 38 (1) 63-73
  PubMedGoogle Scholar
• 60 Mulugeta E, Londos E, Ballard C , et al. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2011; 82 (2) 160-164
  CrossrefPubMedGoogle Scholar
• 61 Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998; 10 (3) 229-238
  CrossrefPubMedGoogle Scholar
• 62 Lanctôt KL, Herrmann N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000; 15 (4) 338-345
  CrossrefPubMedGoogle Scholar
• 63 Samuel W, Caligiuri M, Galasko D , et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15 (9) 794-802
  CrossrefPubMedGoogle Scholar
• 64 Mori E, Ikeda M, Kosaka K ; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72 (1) 41-52
  CrossrefPubMedGoogle Scholar
• 65 Maclean LE, Collins CC, Byrne EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr 2001; 13 (3) 277-288
  CrossrefPubMedGoogle Scholar
• 66 McKeith I, Del Ser T, Spano P , et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356 (9247) 2031-2036
  CrossrefPubMedGoogle Scholar
• 67 Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2011; 32 (4) 227-234
  CrossrefPubMedGoogle Scholar
• 68 Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2014;
  PubMedGoogle Scholar
• 69 Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63 (6) 513-515
  CrossrefPubMedGoogle Scholar
• 70 Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies: a spectrum of disease. Neurosignals 2008; 16 (1) 24-34
  CrossrefPubMedGoogle Scholar
• 71 Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157: 894-901
  CrossrefPubMedGoogle Scholar
• 72 Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A , et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010; 6 (1) 85-95
  PubMedGoogle Scholar
• 73 Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008; 23 (15) 2248-2250
  CrossrefPubMedGoogle Scholar
• 74 McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305 (6855) 673-678
  CrossrefPubMedGoogle Scholar
• 75 Hanagasi HA, Bilgiç B, Emre M. Neuroimaging, biomarkers, and management of dementia with Lewy bodies. Front Neurol 2013; 4: 151
  PubMedGoogle Scholar